Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice

Journal of Neurochemistry

Volumn 114, Issue 6, 2010, Pages 1745-1755

  Käenmäki, Mikko ^a   Tammimäki, Anne ^a,c   Myöhänen, Timo ^a   Pakarinen, Kaisa ^a   Amberg, Carolina ^a   Karayiorgou, Maria ^b   Gogos, Joseph A ^b   Männistö, Pekka T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

catechol O methyltransferase; dopamine; microdialysis; mouse; prefrontal cortex; uptake inhibition

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE TRANSPORTER; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; FEMALE; GENE DISRUPTION; GENOTYPE; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY;

MUS;

ANIMALS; CATECHOL O-METHYLTRANSFERASE; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; MALE; MICE; MICE, KNOCKOUT; MICRODIALYSIS; MONOAMINE OXIDASE INHIBITORS; MUTATION; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX;

EID: 77956327951     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06889.x     Document Type: Article

References (82)

1. Acquas E., Carboni E., de Ree R. H., Da Prada M. Di Chiara G. (1992) Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor RO 40-7592. J. Neurochem. 59, 326 330.
2. Barnett J. H., Jones P. B., Robbins T. W. Müller U. (2007) Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol. Psychiatry 12, 502 509.
3. Bertolino A., Caforio G., Blasi G. et al. (2004) Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 161, 1798 1805.
4. Boudíková B., Szumlanski C., Maidak B. Weinshilboum R. (1990) Human liver catechol-O-methyltransferase pharmacogenetics. Clin. Pharmacol. Ther. 48, 381 389.
5. Budygin E. A., Gainetdinov R. R., Kilpatrick M. R., Rayevsky K. S., Männistö P. T. Wightman R. M. (1999) Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. Eur. J. Pharmacol. 370, 125 131.
6. Buu N. T., Duhaime J. Kuchen O. (1985) Effects of L-dopa on the concentrations of free and sulphoconjugated catecholamines in plasma, celebrospinal fluid, urine and central and peripheral nervous system tissues of the rat. J. Neurochem. 44, 787 792.
7. Carboni E., Tanda G. L., Frau R. Di Chiara G. (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 55, 1067 1070.
8. Cass W. A., Zahniser N. R., Flach K. A. Gerhardt G. A. (1993) Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: role of metabolism and effects of locally applied uptake inhibitors. J. Neurochem. 61, 2269 2278.
9. Chefer V. I., Zapata A., Shippenberg T. S. Bungay P. M. (2006) Quantitative no-net-flux microdialysis permits detection of increases and decreases in dopamine uptake in mouse nucleus accumbens. J. Neurosci. Methods 155, 187 193.
10. Chen J., Lipska B. K., Halim N. et al. (2004) Functional analysis of genetic variation in catechol-O-methyltranserase (COMT): effects on mRNA, protein, and enzyme activity in post-mortem human brain. Am. J. Hum. Genet. 75, 807 821.
11. DeMille M. M., Kidd J. R., Ruggeri V. et al. (2002) Population variation in linkage disequilibrium across the COMT gene considering promoter region and coding region variation. Hum. Genet. 111, 521 537.
12. Di Chiara G., Tanda G. L., Frau R. Carboni E. (1992) Heterologous monoamine reuptake: lack of transmitter specificity of neuron-specific carriers. Neurochem. Int. 20, 231S 235S.
13. Dziedzicka-Wasylewska M., Faron-Górecka A., Kuśmider M., Drozdowska E., Rogóz Z., Siwanowicz J., Caron M. G. Bönisch H. (2006) Effect of antidepressant drugs in mice lacking the norepinephrine transporter. Neuropsychopharmacology 31, 2424 2432.
14. Egan M. F., Goldberg T. E., Kolachana B. S., Callicott J. H., Mazzanti C. M., Straub R. E., Goldman D. Weinberger D. R. (2001) Effect of COMT val108/158met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl Acad. Sci. USA 98, 6917 6922.
15. Eisenhofer G., Kopin I. J. Goldstein D. S. (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 56, 331 349.
16. Enoch M. A., Waheed J. F., Harris C. R., Albaugh B. Goldman D. (2006) Sex differences in the influence of COMT val158met on alcoholism and smoking in plains American Indians. Alcohol. Clin. Exp. Res. 30, 399 406.
17. Eshleman A. J., Carmolli M., Cumbay M., Martens C. R., Neve K. A. Janowsky A. (1999) Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J. Pharmacol. Exp. Ther. 289, 877 885.
18. Forsberg M., Juvonen R. O., Helisalmi P., Leppänen J., Gogos J. A., Karayiorgou M. Männistö P. T. (2004) Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 370, 279 289.
19. Franklin K. B. J. Paxinos G. (1997) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego.
20. Giros B., Wang Y. M., Suter S., McLeskey S. B., Pifl C. Caron M. G. (1994) Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J. Biol. Chem. 269, 15985 15988.
21. Giros B., Jaber M., Jones S. R., Wightman R. M. Caron M. G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606 612.
22. Gogos J. A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D. Karayiorgou M. (1998) Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl Acad. Sci. USA 95, 9991 9996.
23. Gothelf D., Eliez S., Thompson T. et al. (2005) COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat. Neurosci. 8, 1500 1502.
24. Gu H., Wall S. C. Rudnick G. (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269, 7124 7130.
25. Guldberg H. C. Marsden C. A. (1975) Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol. Rev. 27, 135 206.
26. Haasio K., Huotari M., Nissinen E. Männistö P. T. (2003) Tissue histopathology, clinical chemistry and behaviour of adult Comt-gene-disrupted mice. J. Appl. Toxicol. 23, 213 219.
27. He M. Shippenberg T. S. (2000) Strain differences in basal and cocaine-evoked dopamine dynamics in mouse striatum. J. Pharmacol. Exp. Ther. 293, 121 127.
28. Huotari M., Gainetdinov R. Männistö P. T. (1999) Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats. Pharmacol. Toxicol. 85, 233 238.
29. Huotari M., Gogos J. A., Karayiorgou M., Koponen O., Forsberg M., Raasmaja A., Hyttinen J. Männistö P. T. (2002a) Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur. J. Neurosci. 15, 246 256.
30. Huotari M., Santha M., Lucas L. R., Karayiorgou M., Gogos J. A. Männistö P. T. (2002b) Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J. Pharmacol. Exp. Ther. 303, 1309 1316.
31. Huotari M., Garcia-Horsman J. A., Karayiorgou M., Gogos J. A. Männistö P. T. (2004) D-amphetamine responses in catechol-O- methyltransferase (COMT) disrupted mice. Psychopharmacology 172, 1 10.
32. Ichihara K., Nabeshima T. Kameyama T. (1993) Mediation of dopamine D1 and D2 receptors in the effects of GBR 12909 on latent learning and locomotor activity in mice. Eur. J. Pharmacol. 234, 155 163.
33. Javitch J. A., Blaustein R. O. Snyder S. H. (1984) [3H]mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mol. Pharmacol. 26, 35 44.
34. Justice Jr. J. B. (1993) Quantitative microdialysis of neurotransmitters. J. Neurosci. Methods 48, 263 276.
35. Kaakkola S. Wurtman R. J. (1992) Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res. 587, 241 249.
36. Kaakkola S., Männistö P. T. Nissinen E. (1987) Striatal membrane-bound and soluble catechol-O-methyltransferase after selective neural lesions in the rat. J. Neural. Transm. [Gen Sect] 69, 221 228.
37. Karayiorgou M., Altemus M., Galke B. L., Goldman D., Murphy D. L., Ott J. Gogos J. A. (1997) Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc. Natl Acad. Sci. USA 94, 4572 4575.
38. Karayiorgou M., Sobin C., Blundell M. L., Galke B. L., Malinova L., Goldberg P., Ott J. Gogos J. A. (1999) Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. Biol. Psychiatry 45, 1178 1189.
39. Karhunen T., Tilgmann C., Ulmanen I. Panula P. (1995a) Neuronal and non-neuronal catechol-O-methyltransferase in primary cultures of rat brain cells. Int. J. Dev. Neurosci. 13, 825 834.
40. Karhunen T., Tilgmann C., Ulmanen I. Panula P. (1995b) Catechol-O-methyltransferase (COMT) in rat brain: immunoelectron microscopic study with an antiserum against rat recombinant COMT protein. Neurosci. Lett. 187, 57 60.
41. Karoum F., Chrapusta S. J. Egan M. F. (1994) 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J. Neurochem. 63, 972 979.
42. Kopin I. (1984) Catecholamine metabolism: basic aspects and clinical significance. Pharmacol. Rev. 37, 333 356.
43. Lachman H. M., Nolan K. A., Mohr P., Saito T. Volavka J. (1998) Association between catechol O-methyltransferase genotype and violence in schizophrenia and schizoaffective disorder. Am. J. Psychiatry 155, 835 837.
44. Lapish C. C., Ahn S., Evangelista L. M., So K., Seamans J. K. Phillips A. G. (2009) Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex. Psychopharmacology (Berl) 202, 521 530.
45. Li Y. H., Wirth T., Huotari M., Laitinen K., MacDonald E. Männistö P. T. (1998) No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats. Eur. J. Pharmacol. 356, 127 137.
46. Lönnroth P., Jansson P. A. Smith U. (1987) A microdialysis method allowing characterization of intercellular water space in humans. Am. J. Physiol. 253, E228 E231.
47. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melen K. Julkunen I. (1995) Kinetics of human soluble and membrane-bound catechol-O- methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34, 4202 4210.
48. Lundström K., Salminen M., Jalanko A., Savolainen R. Ulmanen I. (1991) Cloning and characterization of human placental catechol-O- methyltransferase cDNA. DNA Cell Biol. 10, 181 189.
49. Männistö P. T. Kaakkola S. (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 51, 593 628.
50. Männistö P. T., Ulmanen I., Lundström K., Taskinen J., Tenhunen J., Tilgmann C. Kaakkola S. (1992) Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog. Drug Res. 39, 291 350.
51. Mata I., Arranz M. J., Staddon S., Lopez-Ilundain J. M., Tabares-Seisdedos R. Murray R. M. (2006) The high-activity Val allele of the catechol-O-methyltransferase gene predicts greater cognitive deterioration in patients with psychosis. Psychiatr. Genet. 16, 213 216.
52. Matsumoto M., Weickert C. S., Akil M., Lipska B. K., Hyde T. M., Herman M. M., Kleinman J. E. Weinberger D. R. (2003) Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience 116, 127 137.
53. Mazei M. S., Pluto C. P., Kirkbride B. Pehek E. A. (2002) Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial PFC of the rat. Brain Res. 936, 58 67.
54. Mijatovic J., Airavaara M., Planken A., Auvinen P., Raasmaja A., Piepponen T. P., Costantini F., Ahtee L. Saarma M. (2007) Constitutive Ret activity in knock-in multiple endocrine neoplasia type B mice induces profound elevation of brain dopamine concentration via enhanced synthesis and increases the number of TH-positive cells in the substantia nigra. J. Neurosci. 27, 4799 4809.
55. Morón J. A., Brockington A., Wise R. A., Rocha B. A. Hope B. T. (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J. Neurosci. 22, 389 395.
56. Munafò M. R., Bowes L., Clark T. G. Flint J. (2005) Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol. Psychiatry 10, 765 770.
57. Mundorf M. L., Joseph J. D., Austin C. M., Caron M. G. Wightman R. M. (2001) Catecholamine release and uptake in the mouse prefrontal cortex. J. Neurochem. 79, 130 142.
58. Myöhänen T. T., Venäläinen J. I., Garcia-Horsman J. A., Piltonen M. Männistö P. T. (2008) Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. J. Comp. Neurol. 507, 1694 1708.
59. Napolitano A., Bellini G., Borroni E., Zurcher G. Bonuccelli U. (2003) Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats. Parkinsonism Relat. Disord. 9, 145 150.
60. Odlind C., Reenilä I., Männistö P. T., Juvonen R., Uhlén S., Gogos J. A., Karayiorgou M. Hansell P. (2002) Reduced natriuretic response to acute sodium loading in COMT gene deleted mice. BMC Physiol. 2, 14.
61. Page M. E. Lucki I. (2002) Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology 27, 237 247.
62. Parsons L. H. Justice Jr. J. B. (1992) Extracellular concentration and in vivo recovery of dopamine in the nucleus accumbens using microdialysis. J. Neurochem. 58, 212 218.
63. Pooley E. C., Fineberg N. Harrison P. J. (2007) The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and meta-analysis. Mol. Psychiatry 12, 556 561.
64. Raux G., Bumsel E., Hecketsweiler B. et al. (2007) Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. Hum. Mol. Genet. 16, 83 91.
65. Rivett A. J., Francis A. Roth J. A. (1983) Distinct cellular localization of membrane-bound and soluble forms of catechol-O-methyltransferase in brain. J. Neurochem. 40, 215 219.
66. Salminen M., Lundström K., Tilgmann C., Savolainen R., Kalkkinen N. Ulmanen I. (1990) Molecular cloning and characterization of rat liver catechol-O-methyltransferase. Gene 93, 241 247.
67. Scatton B., Dubois A., Dubocovich M. L., Zahniser N. R. Fage D. (1985) Quantitative autoradiography of 3Hnomifensine binding sites in rat brain. Life Sci. 36, 815 822.
68. Sesack S. R., Hawrylack V. A., Matus C., Guido M. A. Levey A. I. (1998) Dopamine axon varicosities in the prelimbic division of the rat PFC exhibit sparse immunoreactivity for the dopamine transporter. J. Neurosci. 18, 2697 2708.
69. Sharp T., Zetterström T. Ungerstedt U. (1986) An in vivo study of dopamine release and metabolism in rat brain regions using intracerebral dialysis. J. Neurochem. 47, 113 122.
70. Shen H. W., Hagino Y., Kobayashi H. et al. (2004) Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29, 1790 1799.
71. Smith A. D. Justice J. B. (1994) The effect of inhibition of synthesis, release, metabolism and uptake on the microdialysis extraction fraction of dopamine. J. Neurosci. Methods 54, 75 82.
72. Tammimäki A., Forsberg M., Gogos J., Karayiorgou M. Männistö P. T. (2008) Increase in free choice oral ethanol self-administration in catechol-O-methyltransferase gene-disrupted male mice. Basic. Clin. Pharmacol. Toxicol. 103, 297 304.
73. Tanda G., Carboni E., Frau R. Di Chiara G. (1994) Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl) 115, 285 288.
74. Tanda G., Pontieri F. E., Frau R. Di Chiara G. (1997) Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in rat prefrontal cortex by amphetamine and cocaine. Eur. J. Neurosci. 9, 2077 2085.
75. Trendelenburg U. (1990) The interaction of transport mechanisms and intracellular enzymes in metabolizing systems. J. Neural Transm. Suppl. 32, 3 18.
76. Tunbridge E. M., Bannerman D. M., Sharp T. Harrison P. J. (2004) Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat PFC. J. Neurosci. 24, 5331 5335.
77. Tunbridge E. M., Harrison P. J. Weinberger D. R. (2006) Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry 60, 141 151.
78. Tuomainen P., Törnwall M. Männistö P. T. (1996) Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anaesthetized rats. Pharmacol. Toxicol. 78, 392 396.
79. Weinshilboum R. Raymond F. (1977) Variations in catechol-O- methyltransferase activity in inbred strains of rats. Neuropharmacology 16, 703 706.
80. Wilson V. G., Grohmann M. Trendelenburg U. (1988) The uptake and O-methylation of 3H-(+/-)-isoprenaline in rat cerebral cortex slices. Naunyn Schmiedeberg's Arch. Pharmacol. 337, 397 405.
81. Yamamoto B. K. Novotney S. (1998) Regulation of extracellular dopamine by the norepinehrine transporter. J. Neurochem. 71, 274 280.
82. Yavich L., Forsberg M., Gogos J. A., Karayiorgou M. Männistö P. T. (2007) Site specific role of catechol-O-methyltransferase in dopamine overflow within PFC and dorsal striatum. J. Neurosci. 27, 10196 10202.